Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study
Objective. To investigate the potential benefits of acarbose treatment on cardiovascular disease (CVD) in patients with type 2 diabetes by using nationwide insurance claim dataset. Research Design and Methods. Among 644,792 newly diagnosed type 2 diabetic patients without preexisting CVD in a nation...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2014/812628 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693153217478656 |
|---|---|
| author | Jui-Ming Chen Cheng-Wei Chang Ying-Chieh Lin Jorng-Tzong Horng Wayne H.-H. Sheu |
| author_facet | Jui-Ming Chen Cheng-Wei Chang Ying-Chieh Lin Jorng-Tzong Horng Wayne H.-H. Sheu |
| author_sort | Jui-Ming Chen |
| collection | DOAJ |
| description | Objective. To investigate the potential benefits of acarbose treatment on cardiovascular disease (CVD) in patients with type 2 diabetes by using nationwide insurance claim dataset. Research Design and Methods. Among 644,792 newly diagnosed type 2 diabetic patients without preexisting CVD in a nationwide cohort study, 109,139 (16.9%) who had received acarbose treatment were analyzed for CVD risk. Those with CVD followed by acarbose therapy were also subjected to analysis. Result. During 7 years of follow-up, 5,081 patients (4.7%) developed CVD. The crude hazard ratio (HR) and adjusted HR were 0.66 and 0.99, respectively. The adjusted HR of CVD was 1.19, 0.70, and 0.38 when the duration of acarbose use was <12 months, 12–24 months, and >24 months, respectively. Adjusted HR was 1.14, 0.64, and 0.41 with acarbose cumulative doses <54,750 mg, 54,751 to 109,500 mg, and >109,500 mg, respectively. Conclusion. In patients with type 2 diabetes without preexisting CVD, treatment with acarbose showed a transient increase in incidence of CVD in the initial 12 months followed by significant reductions of CVD in prolonged acarbose users. After the first CVD events, continuous use of acarbose revealed neutral effect within the first 12 months. The underlying mechanisms require further investigations. |
| format | Article |
| id | doaj-art-381d44bc480e4b4bba7c3109a4a38653 |
| institution | DOAJ |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-381d44bc480e4b4bba7c3109a4a386532025-08-20T03:20:30ZengWileyJournal of Diabetes Research2314-67452314-67532014-01-01201410.1155/2014/812628812628Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up StudyJui-Ming Chen0Cheng-Wei Chang1Ying-Chieh Lin2Jorng-Tzong Horng3Wayne H.-H. Sheu4Department of Endocrinology and Metabolism, Tungs’ Taichung MetroHarbor Hospital, Taichung 435, TaiwanDepartment of Information Management, Hsing Wu University, New Taipei City 244, TaiwanDepartment of Biomedical Informatics, Asia University, Taichung 413, TaiwanDepartment of Biomedical Informatics, Asia University, Taichung 413, TaiwanDivision of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, 160, Section 3, Taichung-Harbor Road, Taichung 407, TaiwanObjective. To investigate the potential benefits of acarbose treatment on cardiovascular disease (CVD) in patients with type 2 diabetes by using nationwide insurance claim dataset. Research Design and Methods. Among 644,792 newly diagnosed type 2 diabetic patients without preexisting CVD in a nationwide cohort study, 109,139 (16.9%) who had received acarbose treatment were analyzed for CVD risk. Those with CVD followed by acarbose therapy were also subjected to analysis. Result. During 7 years of follow-up, 5,081 patients (4.7%) developed CVD. The crude hazard ratio (HR) and adjusted HR were 0.66 and 0.99, respectively. The adjusted HR of CVD was 1.19, 0.70, and 0.38 when the duration of acarbose use was <12 months, 12–24 months, and >24 months, respectively. Adjusted HR was 1.14, 0.64, and 0.41 with acarbose cumulative doses <54,750 mg, 54,751 to 109,500 mg, and >109,500 mg, respectively. Conclusion. In patients with type 2 diabetes without preexisting CVD, treatment with acarbose showed a transient increase in incidence of CVD in the initial 12 months followed by significant reductions of CVD in prolonged acarbose users. After the first CVD events, continuous use of acarbose revealed neutral effect within the first 12 months. The underlying mechanisms require further investigations.http://dx.doi.org/10.1155/2014/812628 |
| spellingShingle | Jui-Ming Chen Cheng-Wei Chang Ying-Chieh Lin Jorng-Tzong Horng Wayne H.-H. Sheu Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study Journal of Diabetes Research |
| title | Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study |
| title_full | Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study |
| title_fullStr | Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study |
| title_full_unstemmed | Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study |
| title_short | Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study |
| title_sort | acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients a nationwide seven year follow up study |
| url | http://dx.doi.org/10.1155/2014/812628 |
| work_keys_str_mv | AT juimingchen acarbosetreatmentandtheriskofcardiovasculardiseaseintype2diabeticpatientsanationwidesevenyearfollowupstudy AT chengweichang acarbosetreatmentandtheriskofcardiovasculardiseaseintype2diabeticpatientsanationwidesevenyearfollowupstudy AT yingchiehlin acarbosetreatmentandtheriskofcardiovasculardiseaseintype2diabeticpatientsanationwidesevenyearfollowupstudy AT jorngtzonghorng acarbosetreatmentandtheriskofcardiovasculardiseaseintype2diabeticpatientsanationwidesevenyearfollowupstudy AT waynehhsheu acarbosetreatmentandtheriskofcardiovasculardiseaseintype2diabeticpatientsanationwidesevenyearfollowupstudy |